Osteosarcoma is a rare malignant bone-originating
tumor that usually occurs in young people.
Programmed cell death 1 ligand 1 (PD-L1), an
immune checkpoint protein, is highly expressed in
osteosarcoma tissues. Several recent studies have indicated that the
tumor-related role of PD-L1 in
tumors, especially non-plasma membrane (NPM)-localized PD-L1, is not limited to immune regulation in
osteosarcoma. Here, mass spectrometry analysis is combined with
RNA-seq examination to identify the intracellular binding partners of PD-L1 and elucidate the underlying mechanism of its action. It is found that the NPM-localized PD-L1 interacted with
Insulin-like growth factor binding protein-3 (IGFBP3) to promote
osteosarcoma tumor growth by activating mTOR signaling. This interaction is enforced after phosphoglyceratekinase1 (PGK1)-mediated PD-L1 phosphorylation. Based on these findings, a phosphorylation-mimicking
peptide is designed from PD-L1 and it is encapsulated with a
Cyclic RGD (cRGD)-modified red blood cell membrane (RBCM) vesicle (
Peptide@cRGD-M). The
Peptide@cRGD-M precisely delivers the PD-L1-derived phosphorylation-mimicking
peptide into
osteosarcoma lesions and significantly promotes its
therapeutic effect on the
tumor. Therefore, this investigation not only highlights the function of NPM-localized PD-L1, but also uses an engineering approach to synthesize a small molecular
peptide capable of inhibiting
osteosarcoma growth.